Last reviewed · How we verify
Seasonal trivalent vaccine
The seasonal trivalent influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus, providing protection against seasonal flu infection.
The seasonal trivalent influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus, providing protection against seasonal flu infection. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Seasonal trivalent vaccine |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated or attenuated influenza virus antigens representing three circulating strains (typically two A subtypes and one B lineage). Upon administration, it triggers both humoral and cellular immune responses, leading to the production of strain-specific antibodies and memory B cells that recognize and neutralize the vaccine strains if encountered naturally.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Low-grade fever
- Fatigue
Key clinical trials
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (PHASE3)
- A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision (EARLY_PHASE1)
- Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived) (PHASE3)
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age (PHASE3)
- Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Seasonal trivalent vaccine CI brief — competitive landscape report
- Seasonal trivalent vaccine updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI